Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -44.72k | 62.12% |
| Net profit | -1.18m | 34.06% |
| EBITDA | -1.24m | 49.38% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €85.65m |
Number of shares | 5.53m |
52-week high/low | €22.44 - €13.03 |
| Dividends | No |
Beta | 0.91 |
P/E ratio | -19.63 |
PEG ratio | 1.15 |
P/B ratio | 6.04 |
P/S ratio | 0.00 |
Company profile
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
| Name | BIOCELTIX S.A. ZY -,10 Aktie |
| CEO | Lukasz Piotr Bzdzion |
| Headquarters | Wroclaw,
ds Poland |
| Website | |
| IPO | 08/11/2021 |
| Employees | 49 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Frankfurt | XI3.F |
Warschau | BCX.WA |
